Ifosfamide-induced nephrotoxicity in oncological patients

References

• Bonilla M, Gudsoorkar P, Wanchoo R, et al. Onconephrology 2022: an update. Kidney360. 2023 Feb 1;4(2):258–271. doi: 10.34067/KID.0001582022
   PubMedGoogle Scholar
• Rosner MH, Jhaveri KD, McMahon BA, et al. Onconephrology: the intersections between the kidney and cancer. CA Cancer J Clin. 2021, Jan;71(1):47–77. doi: 10.3322/caac.21636
   PubMed Web of Science ®Google Scholar
• Perazella MA, Shirali AC. Nephrotoxicity of cancer immunotherapies: past, present and future. J Am Soc Nephrol JASN. 2018, Aug;29(8):2039–2052. doi: 10.1681/ASN.2018050488
   PubMed Web of Science ®Google Scholar
• Idle JR, Beyoğlu D. Ifosfamide - history, efficacy, toxicity and encephalopathy. Pharmacol Ther. 2023 Mar;243:108366. doi: 10.1016/j.pharmthera.2023.108366
   PubMed Web of Science ®Google Scholar
• Zhang J, Tian Q, Yung Chan S, et al. Metabolism and transport of oxazaphosphorines and the clinical implications. Drug Metab Rev. 2005 Jan 1;37(4):611–703. doi: 10.1080/03602530500364023
   PubMed Web of Science ®Google Scholar
• Kerbusch T, de Kraker J, Keizer HJ, et al. Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Clin Pharmacokinet. 2001, Jan;40(1):41–62. doi: 10.2165/00003088-200140010-00004
   PubMed Web of Science ®Google Scholar
• Highley MS, Landuyt B, Prenen H, et al. The Nitrogen Mustards. Pharmacol Rev. 2022, Jul;74(3):552–599. doi: 10.1124/pharmrev.120.000121
   PubMed Web of Science ®Google Scholar
• Furlanut M, Franceschi L. Pharmacology of ifosfamide. Oncology. 2003;65(Suppl 2):2–6. doi: 10.1159/000073350
   PubMed Web of Science ®Google Scholar
• Gangireddy M, Nookala V. Ifosfamide. In: StatPearls [internet]. Treasure Island (FL): StatPearls Publishing. 2022. [cited 2022 Nov 8]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK542169/
   Google Scholar
• EMA. European Medicines Agency. Benefits of ifosfamide solutions continue to outweigh risks EMA’s safety committee (PRAC) has concluded that the benefits for infusion. 2021 [cited 2023 Jul 17]. Available from: https://www.ema.europa.eu/en/news/benefits-ifosfamide-solutions-continue-outweigh-risks-emas-safety-committee-prac-has-concluded
   Google Scholar
• Ensergueix G, Pallet N, Joly D, et al. Ifosfamide nephrotoxicity in adult patients. Clin Kidney J. 2020, Aug;13(4):660–665. doi: 10.1093/ckj/sfz183
   PubMed Web of Science ®Google Scholar
• Oberlin O, Fawaz O, Rey A, et al. Long-term evaluation of ifosfamide-related nephrotoxicity in children. J Clin Oncol Off J Am Soc Clin Oncol. 2009 Nov 10;27(32):5350–5355. doi: 10.1200/JCO.2008.17.5257
   Google Scholar
• Leem AY, Kim HS, Yoo BW, et al. Ifosfamide-induced Fanconi syndrome with diabetes insipidus. Korean J Intern Med. 2014, Mar;29(2):246–249. doi: 10.3904/kjim.2014.29.2.246
   PubMed Web of Science ®Google Scholar
• Martinez D, Rodelo J, Pelaez García S. Ifosfamide as a cause of Fanconi syndrome. Cureus. 2022, Mar;14(3):e22755. doi: 10.7759/cureus.22755
   PubMed Web of Science ®Google Scholar
• Zhang J, Lu H. Ifosfamide induces acute renal failure via inhibition of the thioredoxin reductase activity. Free Radic Biol Med. 2007 Dec 15;43(12):1574–1583. doi: 10.1016/j.freeradbiomed.2007.08.020
   PubMed Web of Science ®Google Scholar
• Haque SK, Ariceta G, Batlle D. Proximal renal tubular acidosis: a not so rare disorder of multiple etiologies. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2012, Dec;27(12):4273–4287. doi: 10.1093/ndt/gfs493
   PubMed Web of Science ®Google Scholar
• Arima H, Cheetham T, Christ-Crain M, et al. Changing the name of diabetes insipidus: a position statement of the working group for renaming diabetes insipidus. J Clin Endocrinol Metab. 2023 Jan 1;108(1):1–3. doi: 10.1210/clinem/dgac547
   PubMedGoogle Scholar
• Sohail MA, Hassanein M, Rincon-Choles H. Ifosfamide-induced nephrogenic diabetes insipidus responsive to supraphysiologic doses of intravenous desmopressin. Clin Nephrol Case Stud. 2021;9:87–92. doi: 10.5414/CNCS110589
   PubMedGoogle Scholar
• Skinner R. Chronic ifosfamide nephrotoxicity in children. Med Pediatr Oncol. 2003, Sep;41(3):190–197. doi: 10.1002/mpo.10336
   PubMedGoogle Scholar
• Giraud B, Hebert G, Deroussent A, et al. Oxazaphosphorines: new therapeutic strategies for an old class of drugs. Expert Opin Drug Metab Toxicol. 2010 Aug 1;6(8):919–938. doi: 10.1517/17425255.2010.487861
   PubMed Web of Science ®Google Scholar
• Fujieda M, Matsunaga A, Hayashi A, et al. Children’s toxicology from bench to bed–Drug-induced renal injury (2): nephrotoxicity induced by cisplatin and ifosfamide in children. J Toxicol Sci. 2009;34(Suppl 2):SP251–257. doi: 10.2131/jts.34.SP251
   PubMedGoogle Scholar
• Hałka J, Spaleniak S, Kade G, et al. The nephrotoxicity of drugs used in causal oncological therapies. Curr Oncol. 2022, Dec;29(12):9681–9694. doi: 10.3390/curroncol29120760
   PubMed Web of Science ®Google Scholar
• Ilyas S, Tabasum R, Iftikhar A, et al. Effect of berberis vulgaris L. root extract on ifosfamide-induced in vivo toxicity and in vitro cytotoxicity. Sci Rep. 2021 Jan 18;11(1):1708. doi: 10.1038/s41598-020-80579-5
   PubMed Web of Science ®Google Scholar
• Willits I, Price L, Parry A, et al. Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer. Br J Cancer. 2005 May 9;92(9):1626–1635. doi: 10.1038/sj.bjc.6602554
   PubMed Web of Science ®Google Scholar
• De Chiara L, Lugli G, Villa G, et al. Molecular mechanisms and biomarkers associated with chemotherapy-induced AKI. Int J Mol Sci. 2022, Jan;23(5):2638. doi: 10.3390/ijms23052638
   PubMed Web of Science ®Google Scholar
• Voelcker G. The mechanism of action of cyclophosphamide and its consequences for the development of a New generation of oxazaphosphorine cytostatics. Sci Pharm. 2020, Dec;88(4):42. doi: 10.3390/scipharm88040042
   Web of Science ®Google Scholar
• Akilesh S, Juaire N, Duffield JS, et al. Chronic ifosfamide toxicity: kidney pathology and pathophysiology. Am J Kidney Dis Off J Natl Kidney Found. 2014, May;63(5):843–850. doi: 10.1053/j.ajkd.2013.11.028
   PubMed Web of Science ®Google Scholar
• Ratan R, Patel SR. Chemotherapy for soft tissue sarcoma. Cancer. 2016, Oct;122(19):2952–2960. doi: 10.1002/cncr.30191
   PubMed Web of Science ®Google Scholar
• Gaspar N, Hawkins DS, Dirksen U, et al. Ewing Sarcoma: Current management and future approaches through collaboration. J Clin Oncol Off J Am Soc Clin Oncol. 2015 Sep 20;33(27):3036–3046. doi: 10.1200/JCO.2014.59.5256
   Google Scholar
• Gadducci A, Cosio S. Neoadjuvant chemotherapy in locally advanced cervical cancer: review of the literature and perspectives of clinical research. Anticancer Res. 2020, Sep;40(9):4819–4828. doi: 10.21873/anticanres.14485
   PubMed Web of Science ®Google Scholar
• Buda A, Dell’anna T, Signorelli M, et al. Role of ifosfamide in cervical cancer: an overview. Oncology. 2003;65(Suppl 2):63–66. doi: 10.1159/000073362
   PubMedGoogle Scholar
• Patton SE, Hall MC, Ozen H. Bladder cancer. Curr Opin Oncol. 2002, May;14(3):265–272. doi: 10.1097/00001622-200205000-00003
   PubMed Web of Science ®Google Scholar
• Hussain SA, James ND. The systemic treatment of advanced and metastatic bladder cancer. Lancet Oncol. 2003, Aug;4(8):489–497. doi: 10.1016/S1470-2045(03)01168-9
   PubMed Web of Science ®Google Scholar
• Fukunaga A, Hyuga M, Iwasaki M, et al. Dose-modified ifosfamide, Epirubicin, and etoposide is a safe and effective salvage therapy with high peripheral blood stem cell mobilization capacity for poorly mobilized Hodgkin’s lymphoma and Non-Hodgkin’s lymphoma patients. J Clin Exp Hematop JCEH. 2016 Jun 22;56(1):50–54. doi: 10.3960/jslrt.56.50
   PubMedGoogle Scholar
• Schütt P, Passon J, Ebeling P, et al. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. Eur J Haematol. 2007, Feb;78(2):93–101. doi: 10.1111/j.1600-0609.2006.00796.x
   PubMed Web of Science ®Google Scholar
• Marangolo M, Giovanis P. Ifosfamide in small cell lung cancer. Oncology. 2003;65(Suppl 2):46–49. doi: 10.1159/000073358
   PubMedGoogle Scholar
• Boni C, Zanelli F. Ifosfamide in non-small cell lung cancer. Oncology. 2003;65(Suppl 2):50–54. doi: 10.1159/000073359
   PubMedGoogle Scholar
• Fan XL, Cai GP, Zhu LL, et al. Efficacy and safety of ifosfamide-based chemotherapy for osteosarcoma: a meta-analysis. Drug Des Devel Ther. 2015;9:5925–5932. doi: 10.2147/DDDT.S91217
   PubMed Web of Science ®Google Scholar
• Shin W, Lee HJ, Yang SJ, et al. Retrospective study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer. Obstet Gynecol Sci. 2018, May;61(3):352–358. doi: 10.5468/ogs.2018.61.3.352
   PubMedGoogle Scholar
• Sorio R, Lombardi D, Spazzapan S, et al. Ifosfamide in advanced/disseminated breast cancer. Oncology. 2003;65(Suppl 2):55–58. doi: 10.1159/000073360
   PubMedGoogle Scholar
• Grassin F, Paleiron N, André M, et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma. A French experience. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2010, Jun;5(6):893–897. doi: 10.1097/JTO.0b013e3181db3dee
   Google Scholar
• Girard N, Mornex F, Van Houtte P, et al. Thymoma: a focus on current therapeutic management. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2009, Jan;4(1):119–126. doi: 10.1097/JTO.0b013e31818e105c
   Google Scholar
• Cohen MH, Creaven PJ, Tejada F, et al. Phase I clinical trial of isophosphamide (NSC 109724). Cancer Chemotherrep. 1975;59(4):751–755.
   PubMedGoogle Scholar
• Gharib MI, Burnett AK. Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. Eur J Heart Fail. 2002, Jun;4(3):235–242. doi: 10.1016/S1388-9842(01)00201-X
   PubMed Web of Science ®Google Scholar
• Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf. 2000, Apr;22(4):263–302. doi: 10.2165/00002018-200022040-00002
   PubMed Web of Science ®Google Scholar
• Choi DK, Helenowski I, Hijiya N. Secondary malignancies in pediatric cancer survivors: perspectives and review of the literature. Int J Cancer. 2014;135(8):1764–1773. doi: 10.1002/ijc.28991
   PubMed Web of Science ®Google Scholar
• Long JP, Wan F, Zhang F, et al. DTC chemotherapy regimen is associated with higher incidence of premature ovarian failure in women of reproductive age with breast cancer. Eur Rev Med Pharmacol Sci. 2016;20(6):1087–1092.
   PubMed Web of Science ®Google Scholar
• Sannu A, Radha R, Mathews A, et al. Ifosfamide-induced malignancy of ureter and bladder. Cureus. 2017;9(8):e1594. doi:10.7759/cureus.1594
   PubMedGoogle Scholar
• Nissim I, Horyn O, Daikhin Y, et al. Ifosfamide-induced nephrotoxicity: mechanism and prevention. Cancer Res. 2006 Aug 1;66(15):7824–7831. doi: 10.1158/0008-5472.CAN-06-1043
   PubMed Web of Science ®Google Scholar
• Lee LK, Chen PM, Tzeng CH, et al. Ifosfamide-induced Fanconi’s syndrome. J Cancer Res Pract. 2014 Jun 1;1(1):46–49. doi: 10.1016/S2311-3006(16)30023-4
   Google Scholar
• Sprangers B, Lapman S. The growing pains of ifosfamide. Clin Kidney J. 2020, Aug;13(4):500–503. doi: 10.1093/ckj/sfaa017
   PubMed Web of Science ®Google Scholar
• Rossi R, Pleyer J, Schäfers P, et al. Development of ifosfamide-induced nephrotoxicity: prospective follow-up in 75 patients. Med Pediatr Oncol. 1999, Mar;32(3):177–182. doi: 10.1002/(SICI)1096-911X(199903)32:3<177:AID-MPO3>3.0.CO;2-H
   PubMedGoogle Scholar
• Stöhr W, Paulides M, Bielack S, et al. Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the late effects surveillance System. Pediatr Blood Cancer. 2007, Apr;48(4):447–452. doi: 10.1002/pbc.20858
   PubMed Web of Science ®Google Scholar
• Airy M, Raghavan R, Truong LD, et al. Tubulointerstitial nephritis and cancer chemotherapy: update on a neglected clinical entity. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2013, Oct;28(10):2502–2509. doi: 10.1093/ndt/gft241
   PubMed Web of Science ®Google Scholar
• Skinner R, Parry A, Price L, et al. Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose. Pediatr Blood Cancer. 2010 Jul 1;54(7):983–989. doi: 10.1002/pbc.22364
   PubMed Web of Science ®Google Scholar
• Ingemi AI, Bota VM, Peguero A, et al. Fanconi’s syndrome and nephrogenic diabetes insipidus in an adult treated with ifosfamide. Pharmacotherapy. 2012, Jan;32(1):e12–16. doi: 10.1002/PHAR.1013
   PubMed Web of Science ®Google Scholar
• Kim GH. Pathophysiology of Drug-induced hyponatremia. J Clin Med. 2022 Sep 30;11(19):5810. doi: 10.3390/jcm11195810
   PubMed Web of Science ®Google Scholar
• Berghmans T. Hyponatremia related to medical anticancer treatment. Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 1996, Sep;4(5):341–350. doi: 10.1007/BF01788840
   PubMed Web of Science ®Google Scholar
• Schwerdt G, Gordjani N, Benesic A, et al. Chloroacetaldehyde- and acrolein-induced death of human proximal tubule cells. Pediatr Nephrol (Berlin, Germany). 2006, Jan;21(1):60–67. doi: 10.1007/s00467-005-2006-6
   PubMed Web of Science ®Google Scholar
• Skinner R, Sharkey IM, Pearson AD, et al. Ifosfamide, mesna, and nephrotoxicity in children. J Clin Oncol Off J Am Soc Clin Oncol. 1993, Jan;11(1):173–190. doi: 10.1200/JCO.1993.11.1.173
   PubMed Web of Science ®Google Scholar
• Gupta S, Portales-Castillo I, Daher A, et al. Conventional chemotherapy nephrotoxicity. Adv Chronic Kidney Dis. 2021, Sep;28(5):402–414.e1. doi: 10.1053/j.ackd.2021.08.001
   PubMed Web of Science ®Google Scholar
• Santos MLC, de Brito BB, da Silva FAF, et al. Nephrotoxicity in cancer treatment: an overview. World J Clin Oncol. 2020 Apr 24;11(4):190–204. doi: 10.5306/wjco.v11.i4.190
   PubMed Web of Science ®Google Scholar
• Morales-Alvarez MC. Nephrotoxicity of antimicrobials and antibiotics. Adv Chronic Kidney Dis. 2020, Jan;27(1):31–37. doi: 10.1053/j.ackd.2019.08.001
   PubMed Web of Science ®Google Scholar
• Klaus R, Niyazi M, Lange-Sperandio B. Radiation-induced kidney toxicity: molecular and cellular pathogenesis. Radiat Oncol. 2021 Feb 25;16(1):43. doi: 10.1186/s13014-021-01764-y
   PubMed Web of Science ®Google Scholar
• Ciarimboli G, Holle SK, Vollenbröcker B, et al. New clues for nephrotoxicity induced by ifosfamide: preferential renal uptake via the human organic cation transporter 2. Mol Pharm. 2011 Feb 7;8(1):270–279. doi: 10.1021/mp100329u
   PubMedGoogle Scholar
• Troxell ML, Higgins JP, Kambham N. Antineoplastic treatment and renal injury: an update on renal pathology due to cytotoxic and targeted therapies. Adv Anat Pathol. 2016, Sep;23(5):310–329. doi: 10.1097/PAP.0000000000000122
   PubMed Web of Science ®Google Scholar
• Shabani M, Bayrami D, Moghadam AA, et al. Pretreatment of ellagic acid protects ifosfamide-induced acute nephrotoxicity in rat kidneys: a mitochondrial, histopathological and oxidative stress approaches. Toxicol Rep. 2023 Apr 13;10:441–447. doi: 10.1016/j.toxrep.2023.04.005
   PubMedGoogle Scholar
• Kitterer D, Schwab M, Alscher MD, et al. Drug-induced acid-base disorders. Pediatr Nephrol (Berlin, Germany). 2015, Sep;30(9):1407–1423. doi: 10.1007/s00467-014-2958-5
   PubMed Web of Science ®Google Scholar
• Boskabadi J, Yousefi-Mazhin E, Salehifar E. Ifosfamide-induced acute kidney injury in a patient with leiomyosarcoma: a case report. Cancer Rep Hoboken NJ. 2022, Oct;5(10):e1666. doi: 10.1002/cnr2.1666
   PubMedGoogle Scholar
• Heidari R. The footprints of mitochondrial impairment and cellular energy crisis in the pathogenesis of xenobiotics-induced nephrotoxicity, serum electrolytes imbalance, and Fanconi’s syndrome: a comprehensive review. Toxicology. 2019 Jul 1;423:1–31. doi: 10.1016/j.tox.2019.05.002
   PubMed Web of Science ®Google Scholar
• García-Carro C, Draibe J, Soler MJ. Onconephrology: update in Anticancer Drug-related nephrotoxicity. Nephron. 2023 Mar 21;147(2):65–77. doi: 10.1159/000525029
   PubMed Web of Science ®Google Scholar
• Skinner R, Cotterill SJ, Stevens MC, et al. Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG late effects group study. Br J Cancer. 2000 May;82(10):1636–1645. doi: 10.1054/bjoc.2000.1214
   PubMed Web of Science ®Google Scholar
• Das S, Valencia DN, Fershko A. Partial Fanconi syndrome induced by Ifosfamide. Cureus. 2019 Jan 23;11(1):e3947. doi: 10.7759/cureus.3947
   PubMed Web of Science ®Google Scholar
• Panezai MA, Owen C, Szerlip HM. Partial fanconi syndrome induced by ifosfamide. Proc Bayl Univ Med Cent. 2019, Jan;32(1):73–74. doi: 10.1080/08998280.2018.1536020
   PubMedGoogle Scholar
• Heney D, Lewis IJ, Bailey CC. Acute ifosfamide-induced tubular toxicity. Lancet Lond Engl. 1989 Jul 8;2(8654):103–104. doi: 10.1016/S0140-6736(89)90341-3
   Google Scholar
• Moncrieff M, Foot A. Fanconi syndrome after ifosfamide. Cancer Chemother Pharmacol. 1989;23(2):121–122. doi: 10.1007/BF00273531
   PubMed Web of Science ®Google Scholar
• Newbury-Ecob RA, Noble VW, Barbor PR. Ifosfamide-induced Fanconi syndrome. Lancet Lond Engl. 1989 Jun 10;1(8650):1328. doi: 10.1016/S0140-6736(89)92719-0
   Google Scholar
• Rossi R, Helmchen U, Schellong G. Tubular function and histological findings in ifosfamide-induced renal Fanconi syndrome–a report of two cases. Eur J Pediatr. 1992, May;151(5):384–387. doi: 10.1007/BF02113264
   PubMed Web of Science ®Google Scholar
• Garcia AA. Ifosfamide-induced Fanconi syndrome. Ann Pharmacother. 1995, Jun;29(6):590–591. doi: 10.1177/106002809502900607
   PubMed Web of Science ®Google Scholar
• Ashraf MS, Skinner R, English MW, et al. Late reversibility of chronic ifosfamide-associated nephrotoxicity in a child. Med Pediatr Oncol. 1997, Jan;28(1):62–64. doi: 10.1002/(SICI)1096-911X(199701)28:1<62:AID-MPO12>3.0.CO;2-C
   PubMedGoogle Scholar
• Negro A, Regolisti G, Perazzoli F, et al. Ifosfamide-induced renal Fanconi syndrome with associated nephrogenic diabetes insipidus in an adult patient. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 1998, Jun;13(6):1547–1549. doi: 10.1093/ndt/13.6.1547
   PubMed Web of Science ®Google Scholar
• Kim YI, Yoon JY, Hwang JE, et al. Reversible Proximal Renal Tubular Dysfunction after One-Time Ifosfamide Exposure. Cancer Res Treat. 2010;42(4):244. :
   PubMed Web of Science ®Google Scholar
• Buttemer S, Pai M, Lau KK. Ifosfamide induced Fanconi syndrome. BMJ Case Rep. 2011 Dec 20;2011:bcr1020114950. doi: 10.1136/bcr.10.2011.4950
   PubMedGoogle Scholar
• Gomes SM, Garcia AM, Francisco T, et al. Fanconi syndrome after Ifosfamide exposure – case report. Port J Nephrol Hypertens. 2019;33(1):61–67. doi: 10.32932/pjnh.2019.04.012
   Google Scholar
• Jung Y, Darwish OS. Acquired Fanconi Syndrome from Ifosfamide. Int J Case Rep Ther Stud. 2020 Dec 31 [cited 2022 Nov 6];2(1). doi: 10.24966/CRTS-310X/100013
   Google Scholar
• Kamran SC, Pendergraft WF, Harmon DC, et al. Ifosfamide-induced Fanconi syndrome and desmopressin-responsive nephrogenic diabetes insipidus. Am J Med. 2013, Jul;126(7):e7–8. doi: 10.1016/j.amjmed.2013.02.005
   PubMed Web of Science ®Google Scholar
• Nishimura H, Enokida H, Nagano S, et al. Effects of blood purification therapy on a patient with ifosfamide-induced neurotoxicity and acute kidney injury. J Artif Organs. 2014, Mar;17(1):110–113. doi: 10.1007/s10047-013-0733-1
   PubMed Web of Science ®Google Scholar
• Aleksa K, Woodland C, Koren G. Young age and the risk for ifosfamide-induced nephrotoxicity: a critical review of two opposing studies. Pediatr Nephrol (Berlin, Germany). 2001, Dec;16(12):1153–1158. doi: 10.1007/s004670100053
   PubMed Web of Science ®Google Scholar
• Dobrek L, Nalik-Iwaniak K, Fic K, et al. The effect of acetylcysteine on renal function in experimental models of cyclophosphamide-and ifosfamide-induced cystitis. Curr Urol. 2020, Oct;14(3):150–162. doi: 10.1159/000499245
   PubMedGoogle Scholar
• Chen N, Aleksa K, Woodland C, et al. The effect of N-acetylcysteine on ifosfamide-induced nephrotoxicity: in vitro studies in renal tubular cells. Transl Res J Lab Clin Med. 2007, Jul;150(1):51–57. doi: 10.1016/j.trsl.2007.02.001
   Google Scholar
• El-Sisi AEDE, El-Syaad ME, El-Desoky KI, et al. Protective effects of alpha lipoic acid versus N-acetylcysteine on ifosfamide-induced nephrotoxicity. Toxicol Ind Health. 2015, Feb;31(2):97–107. doi: 10.1177/0748233712469649
   PubMed Web of Science ®Google Scholar
• Chen N, Aleksa K, Woodland C, et al. N-Acetylcysteine prevents ifosfamide-induced nephrotoxicity in rats. Br J Pharmacol. 2008, Apr;153(7):1364–1372. doi: 10.1038/bjp.2008.15
   PubMed Web of Science ®Google Scholar
• Hanly L, Rieder MJ, Huang SHS, et al. N-acetylcysteine rescue protocol for nephrotoxicity in children caused by ifosfamide. J Popul Ther Clin Pharmacol. 2013;20(2):e132–145.
   PubMedGoogle Scholar
• Hanly LN, Chen N, Aleksa K, et al. N-acetylcysteine as a novel prophylactic treatment for ifosfamide-induced nephrotoxicity in children: translational pharmacokinetics. J Clin Pharmacol. 2012, Jan;52(1):55–64. doi: 10.1177/0091270010391790
   PubMed Web of Science ®Google Scholar
• Kamt SF, Liu J, Yan LJ. Renal-protective roles of lipoic acid in kidney disease. Nutrients. 2023, Jan;15(7):1732. doi: 10.3390/nu15071732
   PubMed Web of Science ®Google Scholar
• Hartmann JT, Fels LM, Knop S, et al. A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors. Invest New Drugs. 2000, Aug;18(3):281–289. doi: 10.1023/A:1006490226104
   PubMed Web of Science ®Google Scholar
• Hartmann JT, Knop S, Fels LM, et al. The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors. Anticancer Drugs. 2000, Jan;11(1):1–6. doi: 10.1097/00001813-200001000-00001
   PubMed Web of Science ®Google Scholar
• Chiruvella V, Annamaraju P, Guddati AK. Management of nephrotoxicity of chemotherapy and targeted agents: 2020. Am J Cancer Res. 2020 Dec 1;10(12):4151–4164
   PubMed Web of Science ®Google Scholar
• Eaton A, Egelund T, Ng J. Comparison of rapid hydration and standard hydration prior to ifosfamide administration in pediatric patients: a safety and efficacy study. J Pediatr Pharmacol Ther. 2020;25(3):246–250. doi: 10.5863/1551-6776-25.3.246
   PubMedGoogle Scholar
• Sharbaf FG, Farhangi H, Assadi F. Prevention of chemotherapy-induced nephrotoxicity in children with cancer. Int J Prev Med. 2017 Oct 5;8(1):76. doi: 10.4103/ijpvm.IJPVM_40_17
   PubMedGoogle Scholar